SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gabriel S, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther 2009; 19: 22944.
  • 2
    Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008; 26 Suppl: S3561.
  • 3
    Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? [review]. Arthritis Rheum 2002; 46: 86273.
  • 4
    Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 16907.
  • 5
    Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010; 69: 32531.
  • 6
    Pham T, Gossec L, Constantin A, Pavy S, Bruckert E, Cantagrel A, et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine 2006; 73: 37987.
  • 7
    Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM, et al. Discontinuation of antihyperlipidemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995; 332: 112531.
  • 8
    Tsoneva J, Shaw J. Understanding patients' beliefs and goals in medicine-taking. Prof Nurse 2004; 19: 4668.
  • 9
    Chodick G, Shalev V, Gerber Y, Heymann AD, Silber H, Simah V, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 216779.
  • 10
    Ellis JJ, Erickson S, Stevenson J, Bernstein S, Stiles R, Fendrick M. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004; 19: 63845.
  • 11
    Deambrosis P, Saramin C, Terrazzani G, Scaldaferri L, Debetto P, Giusti P, et al. Evaluation of the prescription and utilization patterns of statins in an Italian local health unit during the period 1994-2003. Eur J Clin Pharmacol 2007; 63: 197203.
  • 12
    Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin 2008; 24: 19872000.
  • 13
    Howell N, Trotter R, Mottram D, Rowe P. Compliance with statins in primary care. Pharm J 2004; 272: 236.
  • 14
    Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164: 20811.
  • 15
    Vinker S, Shani M, Baevsky T, Elhayany A. Adherence with statins over 8 years in a usual care setting. Am J Manag Care 2008; 14: 38892.
  • 16
    Goycochea-Robles M, Rahman MM, Choi H, Esdaile J, Lacaille D. Compliance with statin therapy in rheumatoid arthritis patients [abstract]. Arthritis Rheum 2008; 58 Suppl: S8778.
  • 17
    De Vera M, Choi H, Abrahamowicz M, Rahman MM, Goycochea M, Lacaille D. Non-compliance with statin therapy and risk of acute myocardial infarction in patients with rheumatoid arthritis. Vancouver: Canadian Arthritis Network Annual Scientific Conference; 2009.
  • 18
    De Vera M, Choi H, Abrahamowicz M, Kopec J, Goycochea M, Lacaille D. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2011; 70: 10204.
  • 19
    Penning-van Beest FJ, Termorshuizen F, Goettsch WG, Klungel OH, Kastelein JJ, Herings RM. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007; 28: 1549.
  • 20
    Daskalopoulou S, Delaney J, Filion K, Brophy J, Mayo N, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008; 29: 208391.
  • 21
    Colivicchi F, Bassi A, Santini M, Caltagirone C. Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 2007; 38: 26527.
  • 22
    Ho PM, Spertus JA, Masoudi FA, Reid KJ, Peterson ED, Magid DJ, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 18427.
  • 23
    Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005; 53: 2418.
  • 24
    Province of British Columbia. The 2006 Census of Canada in BC stats. 2006. URL: http://www.bcstats.gov.bc.ca/census.asp.
  • 25
    Schnatter R, Acquavella J, Thompson F. An analysis of death ascertainment and follow-up through Canada's mortality database system. Can J Public Health 1990; 81: 605.
  • 26
    Tu JV, Nardi L, Fang J, Liu J, Khalid L, Johansen H, et al. National trends in rates of death and hospital admissions related to acute myocardial infarction, heart failure and stroke, 1994-2004. CMAJ 2009; 180: E11825.
  • 27
    Goycochea-Robles M, Rahman MM, Choi H, Esdaile JM, Lacaille D. Compliance with statin therapy and predictors of compliance in rheumatoid arthritis (RA) [abstract]. J Rheumatol 2009; 36: 2575.
  • 28
    Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998; 36: 827.
  • 29
    Andrade SE, Gurwitz JH, Chan KA, Donahue JG, Beck A, Boles M, et al. Validation of diagnoses of peptic ulcers and bleeding from administrative databases: a multi-health maintenance organization study. J Clin Epidemiol 2002; 55: 3103.
  • 30
    Smitten A, Simon T, Qi K, Suissa S, Askling J, Franklin J, et al. Malignances in the Abatacept RA Clinical Development Program: an updated epidemiological assessment with > 10,000 person-years of exposure [abstract]. Arthritis Rheum 2008; 58 Suppl: S787.
  • 31
    Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 2008; 59: 107481.
  • 32
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 37383.
  • 33
    Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45: 6139.
  • 34
    Allison P. Survival analysis using the SAS system: a practical guide. Cary (NC): SAS Institute; 1995.
  • 35
    Abrahamowicz M, Tamblyn R. Drug utilization patterns: encyclopedia of biostatistics. Hoboken (NJ): John Wiley & Sons; 2005.
  • 36
    Zhou Z, Rahme E, Abrahamowicz M, Pilote L. Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol 2005; 162: 101623.
  • 37
    Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med 1997; 241: 31725.
  • 38
    The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med 1980; 303: 103841.
  • 39
    Wei L, Fahey T, MacDonald TM. Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol 2008; 66: 1106.
  • 40
    Choi H, Herman M, Seeger J, Robins J, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 11737.
  • 41
    Caplan L, Russell AS, Wolfe F. Steroids for rheumatoid arthritis: the honeymoon revisited (once again). J Rheumatol 2005; 32: 18635.
  • 42
    Ramos-Remus C, Sibley J, Russell AS. Steroids in rheumatoid arthritis: the honeymoon revisited. J Rheumatol 1992; 19: 66770.
  • 43
    Shipton D, Glazier RH, Guan J, Badley EM. Effects of use of specialty services on disease-modifying antirheumatic drug use in the treatment of rheumatoid arthritis in an insured elderly population. Med Care 2004; 42: 90713.
  • 44
    Roussy JP, Bessette L, Bernatsky S, Rahme E, Legare J, Lachaine J. Use of disease-modifying anti-rheumatic drugs for rheumatoid arthritis in Quebec, Canada [abstract]. Arthritis Rheum 2011; 63 Suppl: S855.
  • 45
    MacLean C, Louie R, Leake B, McCaffrey D, Paulus D, Brook R, et al. Quality of care for patients with rheumatoid arthritis. JAMA 2000; 287: 98492.
  • 46
    MacLean CH, Park GS, Traina SB, Liu HH, Hahn BH, Paulus HE, et al. Positive predictive value (PPV) of an administrative data-based algorithm for the identification of patients with rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2001; 44 Suppl: S106.
  • 47
    Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects—advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 3: 72532.
  • 48
    Daskalopoulou S. When statin therapy stops: implications for the patient. Curr Opin Cardiol 2009; 24: 45460.
  • 49
    Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 145862.